Journals / Retina-Vitreus / 2018 / Cilt: 27 - Sayı: 2

Infl uence of Serous Retinal Detachment on the Outcome of Ranibizumab Treatment in Macular Edema Due to Branch Retinal Vein Occlusion in Short Term

Retina Ven Dal Tıkanıklığına Bağlı Makula Ödeminin Tedavisinde Seröz Makula Dekolmanının Ranibizumab Ranibizumab Tedavisi Sonucuna Kısa Dönemde Etkisi

Pages
109–113
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When whole patients were evaluated disruption of the ellipsoid zone rate wasequal in both groups and was correlated with poorer BCVA and increased injection number .

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the infl uence of serous retinal detachment (SRD) on the outcome of intravitreal ranibizumab (IVR) injecton in macular edemadue to branch retinal vein occlusion (BRVO).Material and Methods: Eighteen eyes with cystoid macular edema (CME) and SRD (study group) and 18 eyes with only CME (control group) thatreceived PRN IVR injections during 6 months were evaluated retrospectively.
📊
Key Findings & Data:Outcome measures were changes in central macular thickness (CMT)and best corrected visual acuity (BCVA), injection numbers and the the ellipsoid zone (EZ) status.Results: Mean initial CMT in the study and control groups were 521±119 μm and 462±98 μm, respectively.
💡
Conclusion & Impact:When whole patients were evaluated disruption of the ellipsoid zone rate wasequal in both groups and was correlated with poorer BCVA and increased injection number .
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the infl uence of serous retinal detachment (SRD) on the outcome of intravitreal ranibizumab (IVR) injecton in macular edemadue to branch retinal vein occlusion (BRVO).Material and Methods: Eighteen eyes with cystoid macular edema (CME) and SRD (study group) and 18 eyes with only CME (control group) thatreceived PRN IVR injections during 6 months were evaluated retrospectively. Outcome measures were changes in central macular thickness (CMT)and best corrected visual acuity (BCVA), injection numbers and the the ellipsoid zone (EZ) status.Results: Mean initial CMT in the study and control groups were 521±119 μm and 462±98 μm, respectively. Mean BCVA in the study and controlgroups were 0.93±0.46 and 0.73 ±0.53 LogMAR, respectively. The baseline CMT and BCVA weren’t signifi cantly different between the groups. Themean injection number was 2.88±0.83 in the study and 1.88±0.96 in the control group during the 6 months (p=0.003). At the last visit, the mean decreasein CMT and the improvement in BCVA wasn’t signifi cantly different between the groups.Conclusion: The presence of SRD doesn’t seem to effect the IVR therapy in BRVO negatively, conserning the change in CMT and BCVA. Eyes withSRD received more IVR injections compared to eyes with only CME. When whole patients were evaluated disruption of the ellipsoid zone rate wasequal in both groups and was correlated with poorer BCVA and increased injection number .

Özet

Amaç: Seröz retina dekolmanının (SRD) ven dal tıkanıklığına (VDT) bağlı makula ödeminin intravitreal ranibizumab (İVR) ile tedavisine etkisine değerlendirmek Gereç ve Yöntem: Altı ay içinde PRN İVR enjeksiyonları ile tedavi edilen kistoid makula ödemli (KMÖ) ve SRD’li 18 göz (çalışma grubu) ve yal- nızca KMÖ’lü 18 göz (kontrol grubu) retrospektif olarak değerlendirildi. Santral makula kalınlığı (SMK) ve en iyi düzeltilmiş görme keskinliğindeki (EİDGK) değişiklikler ile enjeksiyon sayıları ve elipsoid zonun (EZ) durumu incelendi. Bulgular: Ortalama başlangıç SMK çalışma ve kontrol gruplarında sırasıyla 521±119 μm ve 462±98 μm olarak bulundu. Ortalama EİDK çalışma ve kontrol gruplarında sırasıyla 0.93±0.46 ve 0.73 ±0.53 LogMAR idi. Başlangıç SMK ve EİDK açısından gruplar arasında anlamlı bir fark yoktu. Altı ay içindeki ortalama enjeksiyon sayısı çalışma grubunda 2.88±0.83 iken kontrol grubunda 1.88±0.96 olarak saptandı (p=0.003). Son kontrolde SMK’da ortalama azalma ve EİDK’da ortalama artış açısından gruplar arasında anlamlı değişiklik bulunmadı. Sonuç: Seröz retina dekolmanının varlığı VDT’ de İVR tedavisini SMK’daki ve EİDK’daki değişiklikler açısından olumsuz etkilemediği görülmüştür. Yalnızca KMÖ’lü olgulara kıyasla SRD’li gözlere daha sık enjeksiyon yapılmıştır. Tüm hastalar incelendğinde elipsoid zondaki bozukluk oranı her iki grupta eşit ve azalmış EİDK ve artmış enjeksiyon sayısıyla ilişkili bulunmuştur.

🔖

Cite This Article

KUMRAL, E. T., ERÇALIK, Y., İMAMOĞLU, S., BARDAK, Y., BARDAK, H., YENEREL, N. M. (2022). Infl uence of Serous Retinal Detachment on the Outcome of Ranibizumab Treatment in Macular Edema Due to Branch Retinal Vein Occlusion in Short Term. Retina-Vitreus, Cilt: 27 - Sayı: 2, 109–113. https://ajindex.com/articles/589164

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Rehak J, Rehak M. Branch retinal vein occlusion: pathogene- sis, visual prognosis, and treatment modalities. Curr Eye Res 2008;33:111–131.
  2. Spaide RF, Lee JK, Klancnik JK Jr, et al. Optical coherence to- mography of branch retinal vein occlusion. Retina 2003;23:343- 347. Shroff D, Mehta DK, Arora R, et al. Natural history of macular status in recent-onset branch retinal vein occlusion: an optical co- herence tomography study. Int Ophthalmol 2008;28:261–268.
  3. Yamaguchi Y, Otani T, Kishi S. Serous macular detachment in branch retinal vein occlusion. Retina 2006;26:1029–1033.
  4. Tsujikawa A, Sakamoto A, Ota M, et al. Serous retinal detach- ment associated with retinal vein occlusion. Am J Ophthalmol 2010;149:291–301.
  5. Battaglia Parodi M, Isola V. Branch retinal vein occlusion and exu- dative retinal detachment: pathogenetical aspects. Ophthalmologi- ca 1994;208:29-31.
  6. Campochiaro PA, Heier JS, Feiner L, et al; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein oc- clusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-1112.
  7. Poon YC, Chen CH, Kuo HK, et al. Clinical implications of serous retinal detachment in branch retinal vein occlusion and response after primary intravitreal bevacizumab injection. J Ocul Pharma- col Ther 2013;29:319-324.
  8. Gallego-Pinazo R, Dolz-Marco R, Pardo-López D, et al. Ranibi- zumab for serous macular detachment in branch retinal vein occlu- sions. Graefes Arch Clin Exp Ophthalmol 2013;251:9-14.
  9. Hoeh AE, Ruppenstine M, Ach T, et al. OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlu- sion. Graefes Arch Clin Exp Ophthalmol 2010;248:1567–1572.
  10. Kang HM, Chung EJ, Kim YM, et al. Spectral-domain optical co- herence tomography (SD-OCT) patterns and response to intra- vitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2013;251:501–508.
  11. Noma H, Funatsu H, Mimura T, et al. Vitreous infl ammatory fac- tors and serous macular detachment in branch retinal vein occlu- sion. Retina 2012;32:86–91.
  12. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: Basic concepts, clinical features and man- agement. Prog. Retin. Eye Res 2008;27:622–647.
  13. Shin HJ, Chung H, Kim HC. Association between integrity of fo- veal photoreceptor layer and visual outcome in retinal vein occlu- sion. Acta Ophthalmol 2011;89:35–40.
  14. Murakami T, Tsujikawa A, Ohta M, et al. Photore